PURPOSE: To investigate the morbidity of higher radiation doses in prostate cancer patients. METHODS AND MATERIALS: Five hundred eighty-five men treated with seed implantation and external beam irradiation were followed a median of 5 years (range, 2-11). Hormonal therapy (HT) of 9 months duration was used in 504 (86.2%) patients. The biologic effective dose (BED) was calculated using an alpha/beta of 2. Urinary incontinence (UI) and symptoms (IPSS) were prospectively collected. Rectal morbidity was scored according to the Radiation Therapy Oncology Group (RTOG) scale. Two BED dose groups of <or=220 Gy (n=449) and >220 Gy (n=136) were used. Comparisons of means were made by Student's t test, and the associations were tested by chi-square analysis (Pearson). RESULTS: Urinary retention developed in 36 (6.2%) and was not associated with BED or IPSS. Retention occurred more often with prostate volume >50 cc (17%, p=0.001). The median change in urinary symptoms (IPSS) was 1. Sixty-one percent with high BED were more likely to have increased postimplant symptoms compared with 39% with lower BED (p=0.025; odds ratio [OR], 1.107; 95% confidence interval [CI], 1.10-1.21). UI occurred in 25 patients (4.3%) and was only associated with a postimplant transurethral resection of the prostate (TURP) (n=25), 16% vs. 2.3% for no TURP (p=0.001; OR, 8; 95% CI, 2.4-27). Of the 373 patients initially potent, 204 (54.7%) maintained potency. Impotence was only associated with age at implant (p=0.001) and HT (p=0.004). Sixty-two (10.6%) patients had Grade 1-2 and 4 patients had Grade 3-4 (0.7%, 2 ulcers and 2 fistulas) rectal complications. Three of the Grade 3/4 complications occurred with a dose <or=220 Gy. CONCLUSION: A BED >220 Gy does not seem to increase morbidity. (c) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
PURPOSE: To investigate the morbidity of higher radiation doses in prostate cancerpatients. METHODS AND MATERIALS: Five hundred eighty-five men treated with seed implantation and external beam irradiation were followed a median of 5 years (range, 2-11). Hormonal therapy (HT) of 9 months duration was used in 504 (86.2%) patients. The biologic effective dose (BED) was calculated using an alpha/beta of 2. Urinary incontinence (UI) and symptoms (IPSS) were prospectively collected. Rectal morbidity was scored according to the Radiation Therapy Oncology Group (RTOG) scale. Two BED dose groups of <or=220 Gy (n=449) and >220 Gy (n=136) were used. Comparisons of means were made by Student's t test, and the associations were tested by chi-square analysis (Pearson). RESULTS: Urinary retention developed in 36 (6.2%) and was not associated with BED or IPSS. Retention occurred more often with prostate volume >50 cc (17%, p=0.001). The median change in urinary symptoms (IPSS) was 1. Sixty-one percent with high BED were more likely to have increased postimplant symptoms compared with 39% with lower BED (p=0.025; odds ratio [OR], 1.107; 95% confidence interval [CI], 1.10-1.21). UI occurred in 25 patients (4.3%) and was only associated with a postimplant transurethral resection of the prostate (TURP) (n=25), 16% vs. 2.3% for no TURP (p=0.001; OR, 8; 95% CI, 2.4-27). Of the 373 patients initially potent, 204 (54.7%) maintained potency. Impotence was only associated with age at implant (p=0.001) and HT (p=0.004). Sixty-two (10.6%) patients had Grade 1-2 and 4 patients had Grade 3-4 (0.7%, 2 ulcers and 2 fistulas) rectal complications. Three of the Grade 3/4 complications occurred with a dose <or=220 Gy. CONCLUSION: A BED >220 Gy does not seem to increase morbidity. (c) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
Authors: E Le Fur; J P Malhaire; D Baverez; F Delage; M A Perrouin-Verbe; F Schlurmann; S Guerif; G Fournier; O Pradier; A Valeri Journal: Strahlenther Onkol Date: 2012-11-11 Impact factor: 3.621